who should not take glp 1 medications Thinking of starting Ozempic, Wegovy, Saxenda, or Tirzepatide? 💉, These GLP-1 have become very popular for diabetes and weight loss—but they're the right choice for everyone., In this 💡Read the full guide here:

The trial results are why everyones talking about them

Per dare unidea (prezzi di listino/indicativi riportati da banche dati o canali di farmacia, quindi variabili): Ozempic (1 penna): circa 168,82 in alcune confezioni Wegovy (1 penna, alcuni dosaggi iniziali): circa 220,00 Saxenda (5 penne): circa 302,88 Mounjaro (4 dosi/penna, alcune confezioni): circa 346,58 Il costo mensile reale dipende da quante penne servono, dal dosaggio prescritto e dalleventuale rimborso (per esempio Mounjaro rimborsato dal 23 febbraio 2025 per il diabete tipo 2 secondo la Nota 100 dell'AIFA)

Differences in vitamin-synthesizing ability of different microbial species might identify the potential mechanism for vitamin variation between healthy individuals and IBS patients

From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever